Solving chronic pain with therapeutic grade psychedelic solutions
Our mastery of biotechnology is pointing the way toward breakthrough therapies for chronic pain and depression.
SOLVING CHRONIC PAIN WITH THERAPEUTIC GRADE PSYCHEDELIC SOLUTIONS
Our mastery of biotechnology is pointing the way toward breakthrough therapies for chronic pain and depression.
We are transforming the treatment of chronic pain, psychiatric ailments and depression by pioneering trials of fixed-dose drugs, combining psilocybin, ketamine, and MDMA, embracing the endless possibilities of micro-dosing.
Shanti holds an import license and license to supply schedule 8 poisons (MDMA and Psilocybin)
Established Telehealth clinic for prescribing Psychedelic drugs
A strong executive team is in place
A University-led clinical trial with the Swinburne Institute of Technology is ready for ethics approval
Prescribing psilocybin, ketamine and MDMA for treating a variety of psychiatric ailments. This will allow national patient access via a medical practitioner using a low-cost online model.
In 2015 to 2018 in the United States, 10.7% of adults used prescription medications in the past 30 days.2
In 2015 to 2018 5.7% of U.S adults used one or more prescription opioids.
3.24 million Australians were living with chronic pain in 2018.3
The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7 billion in 2030.4
It is estimated that one in five Australians experience chronic pain.
BEACH¹ data collected in 2013 indicated 19.2% of patients attending General Practices report chronic pain. Of those 37.7% were graded III / IV (highest pain level).
Medication was used for pain management by 86.1% of patients.
One third of patients were taking Opioids (typically for the higher pain grades).
Our team expands the possibilities of science to create transformative therapies for patients with chronic pain, Psychiatric ailments, and depression—experts in novel drugs Anaesthesiologist, Neuroscientist, Regulatory Affairs cognitive neuroscience, and Cannabinoids.
First mover in the Australian psychedelic space.
Experienced executive team with significant learnings from the cannabis industry.
Strong medical, clinic and research skills
All licenses for import, storage and supplying psychedelics to patients are in place
Psychedelic prescribing clinic established in Australia for Special Access Scheme prescribing
